Changes coming to weight loss drug coverage benefits, effective January 1, 2025 Effective January 1, 2025, Independence Blue Cross (IBX) will no longer offer coverage for drugs including glucagon-like peptide-1 receptor antagonist (GLP-1) and non-glucagon-like peptide-1 receptor antagonist (non-GLP-1) indicated for and prescribed solely for weight loss in the absence of other FDA-approved clinical indications
If you have liver disease, alcohol metabolism is already impaired, and GLP-1 medications further slow hepatic clearance, creating drug accumulation risk
Experts will take into consideration various factors such as your medical history, weight loss goals, preferences, and any existing health conditions.
Its always best to draw from the vial just before use
Let Klinic Lake Mary guide you toward the ideal option tailored to your health needs
Unlike Wegovy , other GLP-1 RAs such as liraglutide , marketed as Saxenda for weight loss, have also been shown to be effective, but with different dosing regimens and side effect profiles
